Prospera Life Sciences Private Limited

Prospera Life Sciences Private Limited is a pharmaceutical company incorporated on September 29, 2022, in Gurgaon, Haryana, India. The company is registered under the Corporate Identification Number (CIN) U24290HR2022PTC106894 and is classified as a private limited company limited by shares. Its authorized and paid-up capital stands at ₹1,000,000 each.

The registered office is located at H No. 400/12, Jacumpura, Near Dr. Jai Bhagwan, Gurgaon, Haryana, 122001. The company is unlisted and operates in the pharmaceutical sector, focusing on the manufacture of chemical products.

As of April 8, 2024, Prospera Life Sciences Private Limited reported zero employees, indicating that it may be in the early stages of its operational phase.

Specific details regarding the manufacturing facilities of Prospera Life Sciences Private Limited are not publicly available. The company's registered address in Gurgaon, Haryana, suggests that its operations are based in this region. However, without explicit information on plant locations, capacities, or specializations, a comprehensive assessment of its manufacturing capabilities cannot be provided.

The company's leadership comprises two directors:

• Nishant Sharma: Director since September 29, 2022.
• Ankush: Director since September 29, 2022.

No additional information regarding other key executives or their roles is available from the provided sources.

Prospera Life Sciences Private Limited's export activities, as reported by TransData Nexus, indicate a total export value of $412,000 USD across 139 shipments from 2022 to 2026. The company's product portfolio includes six finished pharmaceutical formulations across two therapeutic categories: Advanced Oncology (55.6%) and Antiviral & HIV Medications (44.4%). The top five exported products are:

• Lenvatinib: $115,000 USD, Rank #3, 5.4% market share.
• Sofosbuvir: $94,000 USD, Rank #12, 0.2% market share.
• Velpatasvir: $89,000 USD, Rank #9, 0.4% market share.
• Sorafenib: $63,000 USD, Rank #7, 0.4% market share.
• Gefitinib: $47,000 USD, Rank #6, 0.7% market share.

The company's export activities primarily target markets in Southeast Asia, including Thailand, Laos, Singapore, Cambodia, and Malaysia. Notably, in 2025, the company exported approximately $495,000 USD worth of products to Thailand and $575,000 USD to Laos.

Prospera Life Sciences Private Limited has demonstrated a growing presence in emerging markets, particularly in Southeast Asia. The company's export data indicates a significant increase in shipments to countries such as Thailand and Laos, reflecting a strategic focus on these regions. The company's product portfolio, which includes advanced oncology and antiviral medications, aligns with the healthcare needs of these markets, potentially facilitating access through WHO prequalification. However, specific details regarding WHO prequalification status are not available from the provided sources.

The company's export data reveals a concentrated focus on Southeast Asian markets, with Thailand and Laos being primary destinations. This geographic concentration suggests a strategic emphasis on these regions, potentially leveraging proximity and regional trade agreements. While this focus may offer advantages in terms of logistics and market penetration, it also exposes the company to risks associated with overdependence on specific markets. Diversifying its export destinations could mitigate such risks and open avenues in other emerging markets.

Specific information regarding Prospera Life Sciences Private Limited's interactions with the U.S. Food and Drug Administration (FDA), including facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, and inspection history, is not publicly available. The company's export data does not indicate shipments to the United States, suggesting limited or no current market access in the U.S. Without explicit regulatory filings or approvals, a detailed assessment of the company's FDA status cannot be provided.

Information regarding Prospera Life Sciences Private Limited's compliance with World Health Organization (WHO) prequalification, European Union Good Manufacturing Practice (EU GMP) certificates, or European Directorate for the Quality of Medicines & HealthCare (EDQM) status is not available from the provided sources. Given the company's focus on Southeast Asian markets, obtaining WHO prequalification could enhance its credibility and facilitate market access. However, without specific certifications, the company's standing in this regard remains unclear.

Prospera Life Sciences Private Limited is registered with the Ministry of Corporate Affairs (MCA) under the Corporate Identification Number (CIN) U24290HR2022PTC106894. The company's authorized and paid-up capital is ₹1,000,000 each. Specific details regarding manufacturing licenses from the Central Drugs Standard Control Organisation (CDSCO), state drug controller approvals, or export No Objection Certificates (NOCs) are not publicly available. The company's export data indicates shipments of finished pharmaceutical formulations, suggesting compliance with relevant regulatory requirements; however, explicit approvals are not documented.

No information regarding Form 483 observations, warning letters, or import alerts pertaining to Prospera Life Sciences Private Limited is available from the provided sources. The company's export data does not indicate any regulatory issues or compliance concerns in its target markets. However, the absence of such information does not guarantee the absence of regulatory actions.

In the Southeast Asian pharmaceutical market, Prospera Life Sciences Private Limited faces competition from both local and international companies. While specific competitors are not identified in the provided sources, the company's focus on advanced oncology and antiviral medications places it in competition with other pharmaceutical firms offering similar products. The company's export data indicates a significant presence in Thailand and Laos, suggesting a competitive position in these markets. However, without detailed market share data, a comprehensive competitive analysis cannot be conducted.

Prospera Life Sciences Private Limited's product portfolio, which includes advanced oncology and antiviral medications, positions it to address critical healthcare needs in emerging markets. The company's export data indicates a growing presence in Southeast Asia, reflecting successful market penetration strategies. However, the company's reliance on a limited number of products and markets may pose challenges in terms of diversification and risk management.

Prospera Life Sciences Private Limited's current strategic direction appears to focus on exporting finished pharmaceutical formulations, particularly in the therapeutic areas of oncology and antiviral treatments. The company's export data indicates a concentrated presence in Southeast Asian markets, suggesting a targeted approach to market entry and expansion. Future strategic considerations may include diversifying its product portfolio, expanding into additional therapeutic areas, and seeking regulatory approvals in other regions to enhance its global footprint.

Prospera Life Sciences Private Limited's export data indicates a consistent volume of shipments, primarily to Southeast Asian markets. The company's focus on finished pharmaceutical formulations suggests a commitment to quality and compliance with international standards. However, the absence of detailed information regarding manufacturing facilities, certifications, and regulatory approvals limits a comprehensive assessment of the company's reliability as a supplier.

Importers considering Prospera Life Sciences Private Limited as a supplier should verify the following certifications:

• FDA Facility Registration: Confirm the company's registration with the U.S. Food and Drug Administration to ensure compliance with U.S. regulations.
• WHO-GMP Certification: Verify the company's adherence to World Health Organization Good Manufacturing Practice standards to ensure product quality.
• EU GMP Certification: Confirm compliance with European Union Good Manufacturing Practice standards for market access in EU countries.
• ISO Certifications: Assess the company's adherence to international quality management standards.

Verification can be conducted through official regulatory bodies, the company's official communications, or third-party certification organizations.

Importers should undertake the following steps to ensure a thorough evaluation of Prospera Life Sciences Private Limited:

• Verify Regulatory Approvals: Confirm the company's compliance with relevant regulatory bodies, including the FDA, WHO, and EU authorities.
• Assess Manufacturing Capabilities: